Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.63 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191738 | 1.00 | DDB1 (0.63) | DDB1CRBNGPR119HPGDRECQL | |
| SCHEMBL29208509 | 0.94 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL30201627 | 0.94 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL29977355 | 0.94 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL25074522 | 0.94 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL24881041 | 0.94 | CRBN (0.70) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL25193827 | 0.91 | CRBN (0.51) | DDB1CRBNGPR119 | |
| SCHEMBL30441716 | 0.91 | CRBN (0.51) | DDB1CRBNGPR119 | |
| SCHEMBL30066514 | 0.90 | DDB1 (0.66) | DDB1CRBNGPR119MAP4K4 | |
| SCHEMBL24671169 | 0.90 | DDB1 (0.66) | DDB1CRBNGPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | DDB1 675/4885CRBN 218/4885GPR119 3689/4885 |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | DDB1 675/4885CRBN 218/4885GPR119 3689/4885 |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | DDB1 675/4885CRBN 218/4885GPR119 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.